FibroBiologics, Inc. (NASDAQ:FBLG) Insider Hamid Khoja Buys 10,000 Shares of Stock

FibroBiologics, Inc. (NASDAQ:FBLG) insider Hamid Khoja purchased 10,000 shares of the stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $1.90 per share, with a total value of $19,000.00. Following the acquisition, the insider now directly owns 11,250 shares in the company, valued at $21,375. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

FibroBiologics Trading Down 7.1 %

Shares of FibroBiologics stock traded down $0.14 during trading on Monday, hitting $1.83. 278,221 shares of the stock were exchanged, compared to its average volume of 177,141. The business’s 50-day simple moving average is $5.50. FibroBiologics, Inc. has a 12-month low of $1.77 and a 12-month high of $55.00.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that FibroBiologics, Inc. will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroBiologics

Several institutional investors have recently added to or reduced their stakes in FBLG. Fund Evaluation Group LLC purchased a new stake in FibroBiologics in the second quarter valued at $5,265,000. Cascade Financial Partners LLC acquired a new position in FibroBiologics during the second quarter worth approximately $1,572,000. Transform Wealth LLC acquired a new stake in shares of FibroBiologics in the second quarter valued at approximately $668,000. Bank of New York Mellon Corp purchased a new position in shares of FibroBiologics during the second quarter worth approximately $342,000. Finally, RMR Wealth Builders acquired a new position in shares of FibroBiologics in the 2nd quarter valued at $186,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.